Boehringer Ingelheim Animal Health (BIAH) is pleased to announce that Surpass (1% diclofenac sodium) is back on the market after a two-year absence. SURPASS began shipping on Monday, May 15, to existing animal health distributors and veterinarians.
SURPASS is the only FDA-approved topical non-steroidal, anti-inflammatory cream indicated for the control of pain and inflammation associated with osteoarthritis (OA) (hock, knee, fetlock and pastern) in horses. SURPASS is a targeted therapy that delivers relief when and where your horse needs it. Click here to see full label.
“As an important product in the BIAH joint health portfolio, we are excited to offer SURPASS again to our customers,” said Dr. John Tuttle, DVM, director of equine professional services. “Our industry-leading joint health portfolio provides many solutions for veterinarians and horse owners, helping horses reach their full potential every day.”
To learn more about SURPASS, or other products in the BIAH Joint Health Portfolio, visit www.bi-vetmedica.com/species/equine/products/joint_health_portfolio.html or speak with your veterinarian.
IMPORTANT SAFETY INFORMATION: Like any medication, non-steroidal anti-inflammatory drugs (NSAIDs) such as SURPASS may cause side effects. These are usually mild and affect primarily the gastrointestinal system, but more serious side effects can occur. NSAIDs should only be administered under the direction of a licensed professional. SURPASS topical cream is only approved for use in horses and has not been evaluated in breeding, pregnant, or lactating horses, or in horses under 1 year of age. Do not exceed the recommended dose. Wear gloves when administering SURPASS. If direct contact with skin occurs, wash immediately with soap and water. Please refer to the package insert for complete product information.
About Boehringer Ingelheim Animal Health
As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.
Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry’s top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.
